title: Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
abstract: Bryostatin 1, an anti-neoplastic agent and protein kinase C activator, has dose-limiting toxicity manifesting as myalgia. Studies in vivo have suggested that this myalgia may be caused by impairment of oxidative metabolism as mitochondrial capacity, muscle reoxygenation and proton washout from muscle are reduced by bryostatin, possibly as a result of vasoconstriction. To investigate these mechanisms further, and to enable use of bryostatin for prolonged periods, the effect of a vasodilator on the established effects of bryostatin on calf metabolism was studied using 31P magnetic resonance spectroscopy and near infrared spectroscopy. Six patients with disseminated melanoma were examined on four occasions: before and 1 week after initiation of long-term nifedipine (10 mg twice daily) treatment and then 4 and 48 h after bryostatin infusion (25 micrograms m(-2)). Nifedipine impaired muscle oxidative metabolism but had no effect on proton efflux or muscle reoxygenation rate. In the presence of nifedipine, two of the effects of bryostatin, impaired reoxygenation rate and reduced proton efflux, were abolished, but the impaired mitochondrial activity remained. These results show that nifedipine counteracted the vasoconstrictive effect of bryostatin 1. However, because nifedipine itself had an unexpected effect on mitochondrial metabolism, it was not possible to assess whether nifedipine modified bryostatin's effect on this variable. There was no additive detrimental effect of bryostatin on mitochondrial metabolism and nifedipine did not reduce the clinical toxicity of bryostatin 1, which cannot therefore be due to vasoconstriction.
authors.affiliation: MRC Biochemical and Clinical Magnetic Resonance Unit, Oxford Radcliffe Hospital, UK.
authors.forename: C H
authors.initials: CH
authors.lastname: Thompson
authors.forename: V M
authors.initials: VM
authors.lastname: Macaulay
authors.forename: K J
authors.initials: KJ
authors.lastname: O'Byrne
authors.forename: G J
authors.initials: GJ
authors.lastname: Kemp
authors.forename: S M
authors.initials: SM
authors.lastname: Wilner
authors.forename: D C
authors.initials: DC
authors.lastname: Talbot
authors.forename: A L
authors.initials: AL
authors.lastname: Harris
authors.forename: G K
authors.initials: GK
authors.lastname: Radda
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D054713:Bryostatins; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004734:Energy Metabolism / Q000187:drug effects; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007783:Lactones / Q000009:adverse effects*; D018942:Macrolides; D008297:Male; D008875:Middle Aged; D008931:Mitochondria, Muscle / Q000378:metabolism; D018482:Muscle, Skeletal / Q000187:drug effects*; D009543:Nifedipine / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D054713:Bryostatins; D002121:Calcium Channel Blockers; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1; D009543:Nifedipine